HELIX BIOPHARMA Valuation
| HBP Stock | EUR 1.15 0.00 0.00% |
Today, the firm appears to be fairly valued. HELIX BIOPHARMA retains a regular Real Value of €1.15 per share. The prevalent price of the firm is €1.15. Our model calculates the value of HELIX BIOPHARMA from examining the firm fundamentals such as Current Valuation of 29.03 M, net income of (6.56 M), and Price To Book of 50.71 X as well as analyzing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that HELIX BIOPHARMA's price fluctuation is very steady at this time. Calculation of the real value of HELIX BIOPHARMA is based on 3 months time horizon. Increasing HELIX BIOPHARMA's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
HELIX BIOPHARMA's intrinsic value may or may not be the same as its current market price of 1.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.15 | Real 1.15 | Hype 1.15 | Naive 1.15 |
The intrinsic value of HELIX BIOPHARMA's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence HELIX BIOPHARMA's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of HELIX BIOPHARMA helps investors to forecast how HELIX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of HELIX BIOPHARMA more accurately as focusing exclusively on HELIX BIOPHARMA's fundamentals will not take into account other important factors: HELIX BIOPHARMA Total Value Analysis
HELIX BIOPHARMA is currently projected to have takeover price of 29.03 M with market capitalization of 38.94 M, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the HELIX BIOPHARMA fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.03 M | 38.94 M |
HELIX BIOPHARMA Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The newest return on assets of HELIX implies not a very effective usage of assets in November.HELIX BIOPHARMA Profitability Analysis
Net Loss for the year was (6.56 M) with profit before overhead, payroll, taxes, and interest of 0.About HELIX BIOPHARMA Valuation
The stock valuation mechanism determines HELIX BIOPHARMA's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of HELIX BIOPHARMA based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of HELIX BIOPHARMA. We calculate exposure to HELIX BIOPHARMA's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of HELIX BIOPHARMA's related companies.8 Steps to conduct HELIX BIOPHARMA's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates HELIX BIOPHARMA's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct HELIX BIOPHARMA's valuation analysis, follow these 8 steps:- Gather financial information: Obtain HELIX BIOPHARMA's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine HELIX BIOPHARMA's revenue streams: Identify HELIX BIOPHARMA's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research HELIX BIOPHARMA's industry and market trends, including the size of the market, growth rate, and competition.
- Establish HELIX BIOPHARMA's growth potential: Evaluate HELIX BIOPHARMA's management, business model, and growth potential.
- Determine HELIX BIOPHARMA's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate HELIX BIOPHARMA's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for HELIX Stock Analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.